These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8032961)

  • 1. Phase II trial of pirarubicin in the treatment of advanced pancreatic cancer.
    Mahjoubi M; Rougier P; Oliviera J; Herait P; Tigaud JM; Droz JP
    Cancer Invest; 1994; 12(4):403-5. PubMed ID: 8032961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of pirarubicin in the treatment of advanced bladder cancer.
    Mahjoubi M; Kattan J; Ghosn M; Droz JP; Philippot I; Herait P
    Invest New Drugs; 1992 Nov; 10(4):317-21. PubMed ID: 1487407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II clinical study of pirarubicin in hormone resistant prostate cancer.
    Rapoport BL; Falkson G
    Invest New Drugs; 1992 Jul; 10(2):119-21. PubMed ID: 1500266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma.
    Sridhar KS; Hussein AM; Benedetto P; Ardalan B; Savaraj N; Richman SP
    Cancer; 1992 Sep; 70(6):1591-7. PubMed ID: 1516010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trials of tetrahydropyranyl-adriamycin (Pirarubicin) on renal and colon carcinoma, melanoma, and soft tissue sarcoma.
    Roché H; Guiochet N; Kerbrat P; Rebattu P; Fargeot P; Cattan A; Armand JP; Keiling R; Lentz MA; Van Glabeke M
    Am J Clin Oncol; 1993 Apr; 16(2):137-9. PubMed ID: 8452105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of pirarubicin in patients with advanced recurrent head and neck squamous cell carcinoma.
    De Mulder PH; Cappelaere P; Cognetti F; Verweij J; Schornagel JH; Vermorken JB; Kirkpatrick A; Lefebvre JL
    Cancer Chemother Pharmacol; 1994; 33(5):438-40. PubMed ID: 8306420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of pirarubicin.
    Miller AA; Scheulen ME; Kleeberg UR; Seeber S; Schmidt CG
    J Cancer Res Clin Oncol; 1988; 114(1):91-4. PubMed ID: 3162456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
    Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
    Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pirarubicin in advanced non-small cell lung cancer. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer Society.
    Drings P; Günther IU; Gatzemeier U; Berdel W; Stahl M; Salewski E; Edler L
    Onkologie; 1990 Jun; 13(3):180-4. PubMed ID: 2168533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma.
    Frustaci S; Gasparini G; Veronesi A; Tirelli U; Pacciarini MA; Crivellari D; Zagonel V; Monfardini S
    Invest New Drugs; 1987; 5(3):307-9. PubMed ID: 3667167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of 4' deoxydoxorubicin (DXDX) for unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study.
    Rose C; Lad TE; Kilton LJ; Schor J; Rosen ST; Rossof AH; Blough RR; Johnson CM
    Invest New Drugs; 1990 Feb; 8(1):97-9. PubMed ID: 2160920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacological study of intra-arterial hepatic administration of pirarubicin in patients with advanced hepatic metastases.
    Munck JN; Rougier P; Chabot GG; Ramirez LH; Bognel C; Lumbroso J; Herait P; Elias D; Lasser P; Gouyette A
    Eur J Cancer; 1994; 30A(3):289-94. PubMed ID: 8204346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
    Vaughn CB; Salmon SE; Fleming TR
    Invest New Drugs; 1990 Feb; 8(1):81-5. PubMed ID: 2188929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC).
    Holdener EE; Hansen HH; Høst H; Bruntsch U; Cavalli F; Renard J; Pinedo HM; Rozencweig M
    Invest New Drugs; 1985; 3(1):63-6. PubMed ID: 3857219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study.
    Jehn CF; Hemmati P; Lehenbauer-Dehm S; Kümmel S; Flath B; Schmid P
    Clin Breast Cancer; 2016 Dec; 16(6):514-519. PubMed ID: 27395417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
    Grenader T; Goldberg A; Hadas-Halperin I; Gabizon A
    Anticancer Drugs; 2009 Jan; 20(1):15-20. PubMed ID: 19342997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
    McGuire WP; Blessing JA; Berman ML
    Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A phase II trial of pirarubicin in untreated disseminated small cell lung cancer. A cooperative study of the French Pneumo-Cancerology Group].
    Kleisbauer JP; Taytard A; Balmes P; Reynaud-Gaubert M; Vergeret J; Targhetta R; Thomas P; Bonnaud F; Poirier R
    Rev Mal Respir; 1992; 9(2):179-84. PubMed ID: 1314404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pirarubicin for elderly patients with malignant lymphoma.
    Aoki S; Tsukada N; Nomoto N; Maruyama S; Takahashi M; Moriyama Y; Shibata A; Aizawa Y
    J Exp Clin Cancer Res; 1998 Dec; 17(4):465-70. PubMed ID: 10089069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.